178 related articles for article (PubMed ID: 28963907)
1. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease.
Guerrero-Garcia TA; Mogollon RJ; Castillo JJ
Leuk Res; 2017 Nov; 62():12-16. PubMed ID: 28963907
[TBL] [Abstract][Full Text] [Related]
2. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.
Sabry W; Wu Y; Kodad SG
Curr Oncol; 2022 Jul; 29(7):5042-5053. PubMed ID: 35877259
[TBL] [Abstract][Full Text] [Related]
4. [Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH].
Fujishima T; Kawabata Y; Michishita Y; Kitabayashi A; Takahashi N
Rinsho Ketsueki; 2022; 63(10):1386-1391. PubMed ID: 36351644
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Cheng L; Song Q; Liu M; Wang Y; Yi H; Qian Y; Xu P; Cheng S; Wang C; Wang L; Zhao W
Front Immunol; 2021; 12():702593. PubMed ID: 34322131
[TBL] [Abstract][Full Text] [Related]
6. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
7. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
8. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.
Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A
Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
Saba NS; Dang D; Saba J; Cao C; Janbain M; Maalouf B; Safah H
Onkologie; 2013; 36(5):287-91. PubMed ID: 23689224
[TBL] [Abstract][Full Text] [Related]
11. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
Nwanwene K; Khan NAJ; Alsharedi M
J Investig Med High Impact Case Rep; 2021; 9():23247096211017423. PubMed ID: 34032157
[TBL] [Abstract][Full Text] [Related]
12. Oral plasmablastic lymphoma: A case report.
Zizzo M; Zanelli M; Martiniani R; Sanguedolce F; De Marco L; Martino G; Parente P; Annessi V; Manzini L; Ascani S
Medicine (Baltimore); 2020 Sep; 99(39):e22335. PubMed ID: 32991445
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma.
Akce M; Chang E; Haeri M; Perez M; Finch CJ; Udden MM; Mims MP
Case Rep Hematol; 2016; 2016():3598547. PubMed ID: 27957358
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review.
Rodrigues-Fernandes CI; de Souza LL; Santos-Costa SFD; Silva AMB; Pontes HAR; Lopes MA; de Almeida OP; Brennan PA; Fonseca FP
J Oral Pathol Med; 2018 Nov; 47(10):915-922. PubMed ID: 29917262
[TBL] [Abstract][Full Text] [Related]
15. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and survival analysis of eight cases HIV-negative plasmablastic lymphoma].
Han X; Hu LX; Ouyang MQ; Duan MH; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):290-294. PubMed ID: 28468089
[No Abstract] [Full Text] [Related]
17. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
[TBL] [Abstract][Full Text] [Related]
18. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib.
Cencini E; Fabbri A; Guerrini S; Mazzei MA; Rossi V; Bocchia M
Eur J Haematol; 2016 Jun; 96(6):650-654. PubMed ID: 26715026
[TBL] [Abstract][Full Text] [Related]
19. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
20. [Clinical characteristics and survival analysis of 15 cases of HIV-negative plasmablastic lymphoma].
Fu WJ; He MX; Huang AJ; Gao L; Lu GH; Chen J; Chen L; Ni X; Zhang WP; Wang JM; Yang JM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):456-461. PubMed ID: 32654457
[No Abstract] [Full Text] [Related]
[Next] [New Search]
